 |
|
anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103
A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Anti-CD19/anti-CD3 recombinant bispecific monoclonal antibody MT103 posesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonym: | | bispecific T-cell engager MT103 | | | | Code names: | | MEDI-538
MT-103 | | |
|
|
